307 related articles for article (PubMed ID: 36456932)
21. [Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer].
Chen RX; Liu XN; Xu Y; Shi YJ; Wang MQ; Shao C; Huang H; Xu K; Wang MZ; Xu ZJ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Mar; 47(3):207-213. PubMed ID: 38448169
[No Abstract] [Full Text] [Related]
22. [Clinical and chest CT features of immune checkpoint inhibitor-related pneumonitis].
Zhang Q; Zhao SJ; Wang SH; Tao XL; Wu N
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):182-187. PubMed ID: 36781241
[No Abstract] [Full Text] [Related]
23. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC.
Mao Z; Pang G; Huang X; Chen X; Wu J; Xu X; Teng Z; Tan Y; Wang P
BMC Pulm Med; 2024 May; 24(1):253. PubMed ID: 38783253
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients.
He X; Wei SN; Qin WW; Geng N; Li B; Song S; Wang P
Expert Rev Hematol; 2023; 16(12):1135-1142. PubMed ID: 37883026
[TBL] [Abstract][Full Text] [Related]
25. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.
Li X; Yang F; Liu B; Ye L; Du J; Fan X; Yu Y; Li M; Bu L; Zhang Z; Xie L; Li W; Qi J
J Immunother; 2024 Jul-Aug 01; 47(6):220-226. PubMed ID: 38618919
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C
Front Immunol; 2021; 12():818492. PubMed ID: 35095920
[TBL] [Abstract][Full Text] [Related]
28. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease.
Shin SH; Park HY; Im Y; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee HY; Lee SH
Int J Cancer; 2019 Nov; 145(9):2433-2439. PubMed ID: 30807641
[TBL] [Abstract][Full Text] [Related]
29. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Ono K; Ono H; Toi Y; Sugisaka J; Aso M; Saito R; Kawana S; Aiba T; Odaka T; Matsuda S; Saito S; Narumi A; Ogasawara T; Shimizu H; Domeki Y; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
[TBL] [Abstract][Full Text] [Related]
30. Real-world incidence and risk factors of pneumonitis in chemoradiation plus immune checkpoint inhibitors compared with chemoradiation alone in lung cancer: a retrospective cohort study.
Pu D; Liu Q; Zhang S; Wang L; Xu F; Hofman P; Giusti R; Zhou Q; Li X; Li L
Transl Lung Cancer Res; 2024 Jan; 13(1):139-151. PubMed ID: 38405001
[TBL] [Abstract][Full Text] [Related]
31. Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients.
Araki T; Kanda S; Ide T; Sonehara K; Komatsu M; Tateishi K; Minagawa T; Kiniwa Y; Kawakami S; Nomura S; Okuyama R; Hanaoka M; Koizumi T
ESMO Open; 2023 Dec; 8(6):102030. PubMed ID: 37852033
[TBL] [Abstract][Full Text] [Related]
32. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
33. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
34. A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case-Control Study.
Deng H; Deng J; Lin X; Guan W; Lin Z; Qiu Y; Yang Y; Wu J; Qiu G; Sun N; Zhou M; Deng J; Xie X; Xie Z; Liu M; Qin Y; Zhou Y; Zhou C
Clin Drug Investig; 2023 May; 43(5):347-357. PubMed ID: 37097608
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
[TBL] [Abstract][Full Text] [Related]
36. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
Tasaka Y; Honda T; Nishiyama N; Tsutsui T; Saito H; Watabe H; Shimaya K; Mochizuki A; Tsuyuki S; Kawahara T; Sakakibara R; Mitsumura T; Okamoto T; Kobayashi M; Chiaki T; Yamashita T; Tsukada Y; Taki R; Jin Y; Sakashita H; Natsume I; Saitou K; Miyashita Y; Miyazaki Y
Lung Cancer; 2021 May; 155():120-126. PubMed ID: 33798901
[TBL] [Abstract][Full Text] [Related]
37. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
[TBL] [Abstract][Full Text] [Related]
38. Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
Mark NM; Kargl J; Busch SE; Yang GHY; Metz HE; Zhang H; Hubbard JJ; Pipavath SNJ; Madtes DK; Houghton AM
Am J Respir Crit Care Med; 2018 Feb; 197(3):325-336. PubMed ID: 28934595
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Pang L; Xie M; Ma X; Huang A; Song J; Yao J; Deng H; Zhang D; Zang X; Ren F; Gao J; Wu C; Wang Y; Zhang X; Bao X; Pan L; Xue X
BMC Cancer; 2023 Mar; 23(1):203. PubMed ID: 36869304
[TBL] [Abstract][Full Text] [Related]
40. A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer.
Zhang Y; Zhang L; Cao S; Wang Y; Ling X; Zhou Y; Zhong H
Cancer Med; 2023 Aug; 12(15):15998-16010. PubMed ID: 37409360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
